Urologix Announces Hiring of Vice President, Sales and Marketing

MINNEAPOLIS, June 16, 2011 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), a medical device company that develops, manufactures and markets minimally invasive Cooled ThermoTherapy™ (CTT) technology to urologists to provide a durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), announced the appointment of Lisa Ackermann as its Vice President, Sales and Marketing effective June 16, 2011. Ms. Ackermann will report to the Company's Chief Executive Officer, Stryker Warren, Jr. Ms. Ackermann was most recently Group Product Director, Endoscopy for Ethicon Endo-Surgery (EES), a Johnson & Johnson Company. 

"We are excited to welcome Lisa Ackermann to Urologix," stated Mr. Warren. "Lisa brings to Urologix a strong background and passion for developing and leading high performance teams, building and cultivating large Key Opinion Leader networks in both the academic and private medical communities, and maximizing product launches and market development opportunities. We are confident Lisa's significant talents will contribute to our efforts to grow Cooled ThermoTherapy™ as the standard of care for the in-office treatment of BPH."

Ms. Ackermann has spent the past twelve years with Ethicon Endo-Surgery in a variety of roles with increasing responsibility in sales, commercial operations, and marketing. Most recently, she led strategic marketing initiatives in the endoscopy franchise. Previously, she led the US Bariatric Sales Organization through the largest product launch in Ethicon Endo-Surgery history, the REALIZE™ Gastric Band. Her diverse experience and skill set will be a valuable addition to Urologix.

For Subscribers

FOR SUBSCRIBERSAbdul El-Sayed tries to woo MAHA voters as Democrats seek inroads with RFK’s supporters

FOR SUBSCRIBERSKratom-like substances are popping up in a typically benign supplement

FOR SUBSCRIBERSGOP super PAC increases its spending for Sen. Jon Husted in tough Ohio race

FOR SUBSCRIBERSRecords reveal tumultuous marriage between slain New York Times executive and wife

FOR SUBSCRIBERSFrom clean energy warrior to ‘wall of shame,’ James Talarico reverses on a fossil fuel money pledge

FOR SUBSCRIBERSCongressional staff planned official trip with luxury stops in Italy and France weeks before election

FOR SUBSCRIBERSA harrowing ordeal aboard an Israel-bound plane

FOR SUBSCRIBERSOpenAI CEO Sam Altman to skip congressional hearing on rogue AI agents

FOR SUBSCRIBERSKey DOJ lawyers departed Trump ‘grand conspiracy’ probe amid pressure to produce, source says

FOR SUBSCRIBERSTrump’s new AI chatbot often links to a site launched under Clinton 26 years ago

FOR SUBSCRIBERSAt MAHA summit, industry CEOs the movement once vilified take the stage

FOR SUBSCRIBERSThis Paralympian has two goals: Win medals and give away $500,000 to her teammates

FOR SUBSCRIBERSCornell rape allegation spotlights stringent New York state laws that have long drawn criticism

FOR SUBSCRIBERSThe debate over AI’s future rages on both coasts

FOR SUBSCRIBERSDecades-old march dispute reignites in Northern Ireland, threatening political crisis

"Urologix is in the early stages of targeting medical therapy as our principal competitor. I believe in a consultative sales approach, focused on delivering solutions through a clear value proposition and the leverage of clinical data," said Ms. Ackermann. "One of the many aspects that drew me to Urologix is the significant clinical literature to support safety, efficacy and durability of CTT and the Company's commitment to scientific rigor as it continues to draw attention to its definitive, first-line therapy. I am confident we can reach the silently suffering patient on BPH medication who is unaware of a nonsurgical alternative to drugs and show him a durable solution."

About Urologix

For Subscribers

FOR SUBSCRIBERSAbdul El-Sayed tries to woo MAHA voters as Democrats seek inroads with RFK’s supporters

FOR SUBSCRIBERSKratom-like substances are popping up in a typically benign supplement

FOR SUBSCRIBERSGOP super PAC increases its spending for Sen. Jon Husted in tough Ohio race

FOR SUBSCRIBERSRecords reveal tumultuous marriage between slain New York Times executive and wife

FOR SUBSCRIBERSFrom clean energy warrior to ‘wall of shame,’ James Talarico reverses on a fossil fuel money pledge

FOR SUBSCRIBERSCongressional staff planned official trip with luxury stops in Italy and France weeks before election

FOR SUBSCRIBERSA harrowing ordeal aboard an Israel-bound plane

FOR SUBSCRIBERSOpenAI CEO Sam Altman to skip congressional hearing on rogue AI agents

FOR SUBSCRIBERSKey DOJ lawyers departed Trump ‘grand conspiracy’ probe amid pressure to produce, source says

FOR SUBSCRIBERSTrump’s new AI chatbot often links to a site launched under Clinton 26 years ago

FOR SUBSCRIBERSAt MAHA summit, industry CEOs the movement once vilified take the stage

FOR SUBSCRIBERSThis Paralympian has two goals: Win medals and give away $500,000 to her teammates

FOR SUBSCRIBERSCornell rape allegation spotlights stringent New York state laws that have long drawn criticism

FOR SUBSCRIBERSThe debate over AI’s future rages on both coasts

FOR SUBSCRIBERSDecades-old march dispute reignites in Northern Ireland, threatening political crisis

Urologix, Inc., based in Minneapolis, develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders. The Company has developed and offers non-surgical, anesthesia-free, catheter-based treatments that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia (BPH), a condition that affects more than 23 million men worldwide. Urologix' products include the CoolWave® and Targis® control units and the CTC Advance®, Targis® and Prostaprobe® catheter families. All of Urologix' products utilize Cooled ThermoTherapy™ - targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort - and provide safe, effective, lasting relief of the symptoms of BPH.

The Urologix, Inc. logo is available at

CONTACT: Urologix: Stryker Warren, Jr., CEO (763) 475-1400